Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter




Read in Swedish

Vitrolife AB (publ): Interim report January-March 2021: Recovery and good profitability

08:00 / 22 April 2021 Vitrolife Press release

First quarter:
  • Sales amounted to SEK 379 (334) million, corresponding to an increase of 14 percent in SEK. Sales increased by 20 percent in local currency.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 163 (116) million, corresponding to a margin of 43 (35) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 10 million.
  • Net income amounted to SEK 119 (80) million, which gave earnings per share of SEK 1.09 (0.74).

Gothenburg, April 22, 2021
Thomas Axelsson, CEO


Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:

Show as PDF

Show original from Cision


This information was distributed by Cision